David Zaccardelli, Verona Pharma CEO
May 9, 2024 01:23 PM EDT
Financing
Marketing

Verona inks fi­nanc­ing deal worth up to $650M ahead of COPD de­ci­sion

Nicole DeFeudis

Editor

Verona Phar­ma has se­cured up to $650 mil­lion to aid the po­ten­tial launch of its COPD can­di­date en­sifen­trine.

Un­der new

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times